Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New antibody drug shows promise in early lung cancer trial

NCT ID NCT02609776

Ongoing Disease control Sponsor: Janssen Research & Development, LLC Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Jun 24, 2026 · Updated 33 times

Summary

This early-stage trial tests a new drug called amivantamab in people with advanced non-small cell lung cancer. The drug is a special antibody that targets two proteins on cancer cells. Researchers are checking safety and how well it works, both alone and with other treatments. About 751 participants are enrolled.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Study site

    Duarte, California, United States

  • Study site

    La Jolla, California, United States

  • Study site

    Orange, California, United States

  • Study site

    Santa Monica, California, United States

  • Study site

    West Hollywood, California, United States

  • Study site

    Tampa, Florida, United States

  • Study site

    Chicago, Illinois, United States

  • Study site

    Bethesda, Maryland, United States

  • Study site

    Boston, Massachusetts, United States

  • Study site

    Detroit, Michigan, United States

  • Study site

    Rochester, Minnesota, United States

  • Study site

    St Louis, Missouri, United States

  • Study site

    New York, New York, United States

  • Study site

    Portland, Oregon, United States

  • Study site

    Philadelphia, Pennsylvania, United States

  • Study site

    Houston, Texas, United States

  • Study site

    Fairfax, Virginia, United States

  • Study site

    Camperdown, Australia

  • Study site

    Heidelberg, Australia

  • Study site

    Kogarah, Australia

  • Study site

    Murdoch, Australia

  • Study site

    Woolloongabba, Australia

  • Study site

    Toronto, Ontario, Canada

  • Study site

    Beijing, China

  • Study site

    Changchun, China

  • Study site

    Changsha, China

  • Study site

    Chengdu, China

  • Study site

    Chongqing, China

  • Study site

    Guangzhou, China

  • Study site

    Hangzhou, China

  • Study site

    Hefei, China

  • Study site

    Nanchang, China

  • Study site

    Nanjing, China

  • Study site

    Wuhan, China

  • Study site

    Zhengzhou, China

  • Study site

    Bordeaux, France

  • Study site

    Dijon, France

  • Study site

    Lyon, France

  • Study site

    Marseille, France

  • Study site

    Paris, France

  • Study site

    Saint-Herblain, France

  • Study site

    Villejuif, France

  • Study site

    Chūōku, Japan

  • Study site

    Hyōgo, Japan

  • Study site

    Kashiwa, Japan

  • Study site

    Kurume, Japan

  • Study site

    Nagoya, Japan

  • Study site

    Niigata, Japan

  • Study site

    Osaka, Japan

  • Study site

    Tokyo, Japan

  • Study site

    Wakayama, Japan

  • Study site

    Yonago, Japan

  • Study site

    Cheongju-si, South Korea

  • Study site

    Goyang-si, South Korea

  • Study site

    Incheon, South Korea

  • Study site

    Seongnam-si, South Korea

  • Study site

    Seoul, South Korea

  • Study site

    A Coruña, Spain

  • Study site

    Barcelona, Spain

  • Study site

    Madrid, Spain

  • Study site

    Málaga, Spain

  • Study site

    Santander, Spain

  • Study site

    Seville, Spain

  • Study site

    Kaohsiung City, Taiwan

  • Study site

    Taichung, Taiwan

  • Study site

    Taipei, Taiwan

  • Study site

    Manchester, United Kingdom

  • Study site

    Newcastle upon Tyne, United Kingdom

  • Study site

    Sutton, United Kingdom

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Amivantamab (a bispecific antibody targeting EGFR and cMet), given alone or with lazertinib or chemotherapy

What this could lead to

If successful, this could provide a new treatment option for people with advanced non-small cell lung cancer who have not responded to other therapies.

What could go wrong

This is an early phase 1 trial, so the drug may not prove effective or may cause serious side effects. Results may not apply to all patients.

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON SMALL CELL LUNG CANCER NON SMALL CELL LUNG CANCER